ACET Stock Forecast: Adicet Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.14
−13.01% on the day

The median 12-month analyst price target for Adicet Bio, Inc. is $24. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$23.0M
Ticker Nerd rank
30/ 100
Median analyst target
$24
Analysts covering
6
Revenue$0.0
Operating income−$22.3M
Net income−$21.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.0%
1M
−52.7%
YTD
−74.6%
1Y
−76.9%
From 52W high
−79.4%
From 52W low
0.0%
$2
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Accruals
75
Issuance
45
Volatility
37
Quality
31
Revisions
23
Value
11
Momentum
6

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACET stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ACETHigh $55Median $24Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$18
Low
$24
Median
$55
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026GuggenheimMaintainsBuy$90 → $55
29 Sept 2026WedbushMaintainsOutperform$25 → $28
28 Sept 2026HC Wainwright & Co.MaintainsBuy$27 → $34
18 Sept 2026HC Wainwright & Co.ReiteratesBuy$27
6 Aug 2026GuggenheimMaintainsBuy$100 → $90
5 May 2026JefferiesAssumesBuy$8.00 → $19
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026GuggenheimMaintainsBuy—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026Canaccord GenuityMaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025GuggenheimMaintainsBuy—
19 Sept 2025GuggenheimReiteratesBuy—
23 July 2025HC Wainwright & Co.AssumesBuy$4.00
21 Mar 2025GuggenheimReiteratesBuy—
7 Mar 2025Citizens Capital MarketsReiteratesMarket Perform—
7 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Feb 2025JMP SecuritiesReiteratesMarket Perform—
5 Feb 2025HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACET.

Market Radar

This page is one stock. Monday covers all of them.

ACET appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACET vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Adicet Bio, Inc. returned −76.9% against +6.9% for the S&P 500, dividends included.

ACET vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ACETS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACET analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.3×

Cheaper than 92% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−85.9%

Higher than 15% of US stocks

Return on assets
−44.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adicet Bio, Inc. has a market value of $23.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$99.0M.

  • Diluted earnings per share, trailing twelve months: −$11.45.

  • Free cash flow in the twelve months to 30 June 2026: −$85.0M.

  • Shares outstanding: 9.4M.

  • Adicet Bio, Inc. employs 102 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ACET and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACETAdicet Bio, Inc.$23.0M30
AARDAardvark Therapeutics, Inc.$20.1M15
CVMCEL-SCI Corp.$21.1M38
MGXMetagenomi Therapeutics, Inc.$21.2M33
RNAZTransCode Therapeutics, Inc.$19.6M12
IGCIGC Pharma, Inc.$19.5M14
CRVOCervoMed, Inc.$22.1M37

Take a look at ACET’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ACET

What is the ACET stock price forecast for 2026-2027?

The median 12-month analyst price target for Adicet Bio, Inc. is $24, with estimates ranging from $18 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACET stock a buy right now?

Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACET?

As at 21 Nov 2026, Adicet Bio, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will ACET stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $24, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACET stock forecast for 2030?

No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $55 over the next 12 months.

How has ACET stock performed over the past year?

Adicet Bio, Inc. returned -76.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adicet Bio, Inc. do?

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications.

Company

About Adicet Bio, Inc.

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.

CEO Mr. Chen Schor BA, C.P.A., M.B.A. · 102 employees · United States · https://www.adicetbio.com